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Successful antiviral treatment of chronic hepatitis C (HCV), resulting in Sustained Virologic 
Response (SVR) has been shown to reduce the risk for liver related complications, 
hepatocellular carcinoma (HCC) and death. Several studies have also shown that liver 
histology improves after achieved SVR. In a small sub-set of patients, however, liver fibrosis 
will persist and sometimes even progress to cirrhosis after SVR. Furthermore, a risk to 
develop HCC seems to remain many years after SVR has been achieved. The aim of this 
thesis was to study the long-term effect of sustained virologic response on clinical, 
histological and virological outcomes, and to identify risk factors associated with persisting 
advanced fibrosis and a continued risk to develop HCC after SVR. 
In study I we investigated the effect of antiviral treatment on liver-related complications, 
HCC and death. We included 351 patients with HCV related cirrhosis in a prospective cohort 
study. Mean follow-up time was 5.3 years. The risk to develop liver-related complications, 
HCC, and liver-related and all-cause mortality was 0.9, 1.0, 0.7 and 1.9 per 100 person years 
for patients with achieved SVR, compared to 4.9, 4.0, 4.5 and 5.1 per 100 person years for 
patients never treated for HCV. In study II we investigated the prevalence and clinical 
implications of occult hepatitis C. In a cross-sectional study, 54 patients with all stages of 
pre-treatment liver fibrosis and SVR 5-20 years prior to inclusion were tested for HCV RNA 
using a highly sensitive method. Three patients (6%) tested positive for HCV RNA in 
peripheral blood mononuclear cells (PBMCs), but this did not correlate to clinical, 
histological or immunological evidence of persisting liver disease. In study III we 
investigated the long-term risk and risk factors for the development of HCC after achieved 
SVR. In this cohort study we included 399 patients with SVR and pre-treatment advanced 
fibrosis or cirrhosis. Median follow-up time was 7.8 years. The incidence rate of HCC was 
0.15 and 0.95 per 100 person years for patients with advanced fibrosis and cirrhosis 
respectively. The main risk factor for the development of HCC was pre-treatment cirrhosis, 
low serum albumin and diabetes mellitus. The risk to develop HCC diminished with longer 
follow-up time. In study IV we investigated fibrosis regression and risk factors for persisting 
advanced fibrosis after achieved SVR. In a cross-sectional study 269 patients were examined 
with transient elastography. Median follow-up time was 7.7 years. A majority of patients 
regressed to a lower fibrosis stage at follow-up, but 24% had persisting advanced fibrosis. 
This proportion, however, diminished over time. Risk factors associated with persisting 
advanced fibrosis were pre-treatment cirrhosis, higher age and high body mass index. 
Our studies have contributed to the growing evidence of the positive effects of SVR in 
chronic HCV. With long follow-up time, we were also able to show that disease regression 
continues over time. We identified established cirrhosis and co-morbidity with metabolic 
disease as important risk factors for persisting advanced fibrosis and a continued risk to 
develop HCC after SVR has been achieved. 
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1 INTRODUCTION 
Chronic infection with hepatitis C virus (HCV) is a global health problem. It is estimated that 
70 million people are chronically infected with HCV and that 750 000 people die every year 
from HCV related causes [1, 2]. Chronic HCV infection is a major cause of hepatocellular 
carcinoma (HCC) in the world and has been the leading cause for liver transplantation in 
North America and Europe [3, 4]. Treatment with interferon-based therapy was introduced in 
1986, even before the virus was identified, but was ineffective and burdened by side effects 
[5]. As a consequence, for many years the main focus of HCV research was the development 
of better treatment strategies. Twenty years later combination therapy with pegylated 
interferon and ribavirin cured 50% of the treated patients but often failed to cure patients with 
more advanced liver disease and a high risk of liver-related and other complications [6]. With 
the development of direct-acting antivirals (DAAs) this has changed, and we can now achieve 
virologic cure (sustained virologic response – SVR) in almost all patients regardless of the 
stage of liver disease [7]. 
This raises other questions. What is the effect of SVR on clinical outcomes? Can liver 
fibrosis and cirrhosis regress after SVR has been achieved? Does SVR really mean that HCV 
has been eradicated, or can small amounts of HCV persist in liver tissue or immune cells?  
The aim of this thesis was to investigate the long term effect of SVR on clinical, histological 
and virological outcomes. Is successful treatment of chronic hepatitis C really a cure? 
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2 HEPATITIS C INFECTION 
2.1 HEPATITS C VIRUS 
The clinical picture of hepatitis C infection was first described as transfusion-associated non-
A non-B hepatitis in 1975 [8]. Hepatitis C virus (HCV) was isolated in 1989, and was found 
to be a positive sense, single-stranded RNA virus belonging to the Flaviviridae family [9]. 
The HCV particle consists of a lipid membrane envelope and a nucleocapsid, containing the 
HCV genome. The HCV genome codes for a single polyprotein that is cleaved by viral and 
cellular proteases into three structural (core and envelope 1+2) and seven non-structural 
proteins (P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). HCV replication is dependent on 
the combined functions of the NS3/4A protease complex, the NS5B RNA polymerase and the 
NS4B and NS5A proteins [10]. Increased knowledge of these viral proteins has led to the 
development of new direct-acting antiviral drugs [11]. There are seven genotypes (GT 1-7) 
and several sub-genotypes of HCV, and the genetic diversity of HCV is enormous [12]. This 
is due to the high error rate of the NS5B RNA polymerase, but also to the long evolutionary 
relationship between HCV and humans [13, 14]. HCV genotypes have epidemiologic 
implications, but also affect the outcome of hepatitis C treatment [15]. 
 
 
Figure 1: Hepatitis C virus particle and viral proteins 
 
2.2 EPIDEMIOLOGY OF HCV INFECTION 
Chronic infection with HCV is a global health problem and a growing epidemic with a 
seroprevalence that has increased from 2.3% to 2.8% between 1990 and 2005 [16]. Based on 
serologic evidence of infection it has been estimated that130-170 million people are 
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chronically infected with HCV [16, 17]. These estimations have been challenged, and recent 
studies using updated data on viraemic infections have estimated that 70-80 million have 
chronic HCV infection [1, 18]. The burden of disease is not evenly distributed globally, with 
the highest viraemic HCV prevalence in Eastern Europe and Central Asia [1]. There are 
several explanations for the new lower estimates for HCV prevalence. Older statistics have 
been incomplete and outdated, and new lower estimates for populous countries like China 
and India influenced the total prevalence significantly [1]. Another reason is that patients with 
chronic HCV are an ageing population which have already developed advanced liver disease 
and consequently have a high mortality rate [19, 20]. In many countries the rate of all-cause 
and liver related mortality among HCV infected people is higher than the rate of new 
infections, decreasing the HCV prevalence [1]. As a consequence the global morbidity and 
mortality caused by chronic HCV infection has increased by more than 50% between 1990-
2013 despite a lower HCV prevalence, and 500 000-750 000 people now die from HCV 
related causes every year [2, 21].  
 
 
Figure 2: Estimated viraemic HCV prevalence in 2015. From Bach S et al, The Lancet 
Gastroenterology 2017, http://dx.doi.org/10.1016/S2468-1253(16)30181-9, with permission: 
http://creativecommons.org/licenses/by-nc-nd/4.0/. 
 
Hepatitis C virus infection is an almost exclusively blood-borne disease, and the main routes 
of transmission are intravenous drug use and nosocomial transmission through transfusions or 
contaminated health care equipment [22]. Vertical transmission from mother to child is rare 
and occurs in 4-7% of pregnancies [23]. Sexual transmission is very rare, but higher 
incidence rates have been reported mainly among human immunodeficiency virus (HIV) co-
infected men who have sex with men [24, 25]. 
In Sweden the spread of HCV increased during the 1960s to 1980s, as a result of injecting 
drug use. HCV infection is widespread among people who inject drugs in Sweden, and the 
seroprevalence of HCV in this group has been estimated to be over 80% [26]. Over 50 000 
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people have been diagnosed with HCV infection in Sweden since 1990, correlating to a 
seroprevalence of 0.5%, compared to over 2% in other Western European countries [16, 27]. 
It has been estimated that approximately 20% of HCV infected persons in Sweden have an 
undiagnosed infection [28]. 
 
2.3 NATURAL HISTORY OF HCV INFECTION 
The incubation period for HCV infection is 2-6 months, but only 20% of HCV infected 
patients develop a clinical acute hepatitis with jaundice. The majority of acute HCV 
infections are instead subclinical and anicteric. Approximately 15-25% of HCV infected 
patients will clear the infection spontaneously and the rest develop chronic hepatitis C, 
defined as persisting HCV RNA after more than six months [29]. Young patients, women and 
patients with symptomatic acute hepatitis have a much higher rate of spontaneous clearance 
and the risk for chronic infection for these groups is only 55-60% [30]. 
 
 
Figure 3: The natural history of HCV infection. HCC=hepatocellular carcinoma, ESLD=end 
stage liver disease. From Hepatitis C Online: http://www.hepatitisc.uw.edu, with permission. 
 
Patients who develop chronic HCV infection are at risk for continued hepatic inflammation 
and fibrosis that will progress slowly over decades. After 20-40 years of chronic HCV 
infection, 20% of patients will have developed advanced liver disease with cirrhosis or 
hepatocellular carcinoma(HCC) [30]. Disease progression is not linear and the risk for 
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advanced liver disease increases with older age [31]. The risk for liver-related complications, 
HCC and liver-related death is low for patients with mild fibrosis, but increases with the stage 
of fibrosis. The annual risk to develop HCC for patients with chronic hepatitis C and cirrhosis 
is approximately 4% in the Western world, while higher estimates have been reported in 
Eastern Asia [32, 33]. Patients with advanced fibrosis, who have not yet developed cirrhosis, 
also seem to have a risk to develop HCC, with reported annual risks of 0.8-3.4% [34, 35]. 
Current guidelines from The European Association for the Study of the Liver (EASL) 
therefore recommend HCC surveillance with ultrasound every 6 months for patients with 
HCV infection and advanced fibrosis or cirrhosis [36]. Because of this, accurate measurement 
of hepatic fibrosis is important for the clinical management of patients with chronic HCV 
infection. 
 
2.4 MEASUREMENT OF LIVER FIBROSIS 
The gold standard for measuring the stage of liver fibrosis is by liver biopsy. A liver biopsy 
also provides information on hepatic necroinflammatory activity. It is, however, an invasive 
method, associated with pain and potentially serious complications. The most widely 
accepted scoring systems for assessment of liver fibrosis and necroinflammation are the Ishak 
and METAVIR scores [37, 38]. Both scoring systems measure fibrosis and inflammation 
separately, but use different scales. The METAVIR system describes five stages of fibrosis, 
with stage F0 correlating to absence of fibrosis and stage F4 to cirrhosis. The grade of 
inflammation is similarly divided into four steps, A0-3. 
 
 
Figure 4. Fibrosis stages F0-F4 according to the METAVIR system: (a) No fibrosis, F0. (b) 
Portal and periportal fibrosis, F1. (c) Periportal fibrosis with few septa, F2. (d) Septal 
fibrosis and bridging without cirrhosis, F3. (e) Cirrhosis, F4. 
© 2013 Macarini L, Stoppino LP. Published in Radiologic Assessment of Liver Fibrosis – 
Present and Future, Practical Management of Chronic Viral Hepatitis under CC BY 3.0 
license. Available from: http://dx.doi.org/10.5772/55164, with permission. 
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A non-invasive alternative to liver biopsy is transient elastography. This method measures 
liver stiffness by ultrasound and the result is a composite variable measuring both liver 
fibrosis and inflammation. The method is validated for the diagnosis of significant fibrosis 
and cirrhosis in chronic hepatitis C [39]. An advantage of transient elastography is that since 
the outcome is a continuous variable, it is possible to stratify the degree of cirrhosis within 
the cirrhotic group and to correlate this to clinical outcome [40]. A drawback of transient 
elastography is that it will also measure increased liver stiffness due to other causes, such as 
recent food-intake, congestive heart disease and acute hepatitis. The method is also less 
validated for the assessment of residual liver fibrosis after successful treatment of chronic 




Figure 5: Clinical cut-offs for liver stiffness measurements and corresponding fibrosis stage 
according to the METAVIR scoring system. From Castera L et al, Journal of Hepatology 
2008: http://dx.doi.org /10.1016/j.jhep.2008.02.008, with permission. 
 
Another method to describe the severity of liver cirrhosis is by the Child-Pugh score, which is 
also used to assess the prognosis for patients with liver cirrhosis. This score combines 
biochemical markers (serum albumin, bilirubin and INR) and clinical complications (ascites 
and hepatic encephalopathy) to calculate a score of 5-15 points. The results are then grouped 
as Child-Pugh class A, B and C with increasing severity and reduction of life-expectancy 
[42]. 
 
2.5 HCV IMMUNOLOGY 
Within 1-2 weeks after infection with HCV the patient becomes viraemic and the innate 
immune system reacts with an interferon (IFN) driven response to control viral replication 
[43, 44]. This response is not able to clear the infection and after a delay of 1-2 months the 
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adaptive immune system responds by recruiting HCV specific T-cells to the liver [43, 45]. 
The adaptive immune response consists of neutralizing antibodies and HCV specific cytolytic 
and non-cytolytic T-cell responses [46]. A dominating IFN-γ mediated non-cytolytic 
response correlates strongly with viral clearance and normalized liver blood tests, but this 
occurs in less than a third of acute HCV infections [43].  
In patients that develop chronic infection, HCV somehow evades the adaptive immune 
response, and in many cases instead stimulate an ineffective IFN-mediated innate immune 
response in the liver [47]. This response has been associated with a genetic polymorphism in 
the IL28B gene, which is also associated with a poor response to IFN based antiviral therapy 
[48, 49]. 
 
2.6 TREATMENT OF HCV INFECTION 
The goal of HCV treatment is virological cure in order to prevent HCV related complications 
such as fibrosis, cirrhosis, decompensated liver disease, hepatocellular carcinoma and death 
[7]. Virological cure is defined as undetectable HCV RNA 12-24 weeks after end of antiviral 
treatment, and is usually described as sustained virologic response or SVR [50]. The first 
attempts to treat HCV infection with recombinant human alpha-interferon were performed 
before the virus could be isolated and the clinical endpoint at this time was normalized serum 
aminotransferase levels [5]. Early attempts to treat HCV infection with ribavirin in 
monotherapy, led to high rates of clinical relapse [51, 52]. The combination of alpha-
interferon and ribavirin, and later the development of pegylated interferon improved 
treatment results substantially with SVR rates of 40-80%, depending on HCV genotype and 
the stage of liver fibrosis [53-55]. However, IFN-based treatments were also associated with 
substantial side-effects, such as flu-like symptoms, depression, anemia and autoimmune 
hepatitis. Several patient groups with co-morbidities were therefore excluded from treatment. 
Patients with cirrhosis had a much lower chance of SVR, and patients with advanced 
cirrhosis tolerated IFN-based treatment poorly due to a risk for hepatic decompensation and 
infection [6]. As a consequence, patients with cirrhosis had both a high risk of liver-related 
complications and a low rate of SVR.  
Since 2011, new highly effective antivirals, directly targeting viral proteins involved in 
replication such as NS3/4A protease inhibitors, NS5A inhibitors and NS5B polymerase 
inhibitors, have further improved treatment results. These direct-acting antivirals (DAAs) 
allow interferon-free treatment with SVR rates > 95% for all patients, regardless of genotype 
and stage of liver fibrosis [56-59]. The side-effects are generally mild and not frequent. As a 
result more patients with more advanced liver disease will achieve SVR in the coming years, 
and questions about how this will affect their clinical outcome becomes more important. 
  
 14 
3 EFFECT OF SVR 
3.1 LIVER-RELATED COMPLICATIONS, HCC AND MORTALITY 
Sustained virologic response (SVR) is only a surrogate marker for the clinical end-point of 
successful antiviral treatment of chronic HCV. The ultimate goal of HCV treatment is to 
reduce the risk for liver-related complications, HCC and death [7]. Several studies have 
shown that the risk for liver-related complications and HCC decreases after SVR has been 
achieved [60-64]. A meta-analysis in 2010 estimated that achieved SVR reduces the risk for 
HCC in patients with HCV associated advanced liver disease by 68% (relative risk (RR) 0.32, 
95% confidence interval (CI) 0.23-0.44), and the risk for decompensated liver disease by 
87% (RR 0.13, 95% CI 0.06-0.27) [65]. Later studies have confirmed that the risk for liver-
related complications, such as esophageal varicosal bleeding and hepatic decompensation 
after SVR is very low, but also that a risk for HCC remains [35, 66-68]. With longer follow-
up time and growing cohorts of patients with SVR we now also know that SVR is associated 
with reduced liver-related mortality and longer over-all survival [68, 69]. 
The risk to develop HCC after SVR and risk factors associated with HCC development has 
been investigated in several studies on different populations. The largest studies have been 
performed in Asian cohorts, where the risk to develop HCC is generally higher and not as 
strongly associated with cirrhosis [70]. As a consequence these studies have included patients 
with all stages of liver fibrosis and only a small proportion of patients with pre-treatment 
cirrhosis. Almost all of these studies have associated the risk to develop HCC with more 
advanced fibrosis and higher age before treatment [60-62, 71-75]. Other risk factors, such as 
male gender, alcohol use, diabetes mellitus, liver steatosis and different biochemical markers 
of liver disease have been associated with a risk to develop HCC in some studies, but not in 
others [71, 73, 75-77]. The results from these studies are not automatically applicable on 
patients from Western cohorts with other environmental and genetic backgrounds. 
In Western patients there is a strong association between advanced liver disease and the risk 
to develop HCC [70]. Studies on the risk to develop HCC after SVR in Western cohorts have 
therefore included a high proportion of patients with cirrhosis before treatment. As a 
consequence the number of patients with SVR included has been lower than in Asian studies, 
and it has been difficult to identify risk factors associated with the risk to develop HCC after 
SVR.  
It is also not known if the risk to develop HCC after SVR decreases over time. Case reports 
of patients that develop HCC more than 17 years after SVR showed that the risk can persist 
for many years [78]. Current guidelines therefore recommend continued HCC surveillance 
with ultrasound every six months in high risk groups also after SVR has been achieved [36].  
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incidence or IR 
of HCC SVR 
Cumulative 
incidence or IR 
of HCC non-SVR 
Risk factors for HCC in 
patients with SVR 
Yoshida [60] Japan 2392/836 (9%) Mean 6.7-7.4 IR 0.57 IR 2.16 ↑fibrosis, ↑age 
Makiyama [61] Japan 3626/1197 (2%) Mean 5.9 2.3 8.8 ↑fibrosis, ↑age, male  
Iwasaki [71] Japan 792/792 (2%) Median 5.1 2.9 - ↑fibrosis, ↑age, alcohol 
Kobayashi [62] Japan 1124/373 (?) Median 5.5 3.5 8.1 ↑fibrosis, ↑age, male  
Hirakawa [72] Japan 1193/1193(3%) Median 8.3 1.9 - ↑fibrosis, ↑age, male  
Tanaka [73] Japan 266/266(3%) Mean 9.9 2.6 - ↑fibrosis, ↑age, 
↑steatosis 
Chang [74] Taiwan 871/871 (28%) Median 3.4 4.2 - ↑fibrosis, ↓platelets, 
↑age, ↑ 
Asahina [76] Japan 1818/913 (?) Mean 6.1 2.3 6.9 ↑alanine transaminase, 
↑α-fetoprotein 
Hung [77] Taiwan 1470/1027 (28%) Median 4.4 3.2 12.2 Diabetes in patients 
without cirrhosis 
Huang [75] Taiwan 642/642 (13%) Median 4.4 IR 0.68 IR 4.54 F4, ↑age, ↑γ-glutamyl 
transferase 
Veldt [63] Europe/Canada 479/142 (75%) Median 2.1 IR 1.07 IR 2.77 Not assessed 
Bruno [64] Italy 883/124 (100%) Mean 8.0 IR 0.66 IR 2.10 Not assessed 
Cardoso [35] France 307/103 (59%) Median 3.5 IR 1.24 IR 5.85 Not assessed 
Morgan [67] USA 526/140 (35%) Median 6.6-
7.2 
1.4 8.5 Not assessed 
Van der Meer [68] Europe/Canada 530/192 (73%) Median 8.4 IR 0.55 IR 2.63 Not assessed 
Table 1: Summary of studies investigating the risk for HCC after achievement of SVR in 
patients with HCV. The risk is described either as a cumulative incidence or an incidence 
rate (IR). The table only includes risk factors for HCC in patients with SVR. 
 
3.2 LIVER FIBROSIS 
Another important question is whether fibrosis and cirrhosis can regress after successful 
antiviral treatment of chronic HCV infection or not. To answer this, several studies with 
varying follow-up times have compared liver fibrosis by different methods before and after 
achievement of SVR [41, 79-87]. 
Studies based on liver biopsies have all shown that fibrosis and cirrhosis can improve after 
SVR has been achieved in a majority of patients, but also that fibrosis will persist or progress 
after SVR in a subset of 1-14% [79-83]. The studies with the shortest mean follow-up times 
reported the highest rate of fibrosis progression, whereas studies with longer mean follow-up 
times reported lower rates of 1-7%. In the largest study, with 3010 patients of which 1094 
achieved SVR, cirrhosis regressed in 75 of 153 patients (49%) and fibrosis progressed in 7% 
of patients with SVR. Mean follow-up time was 20 months, and factors strongly associated 
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with absence of significant fibrosis after treatment was achieved SVR, lower baseline fibrosis 
stage, age below 40 and a BMI below 27 [79]. 
Due to the risks associated with liver biopsies, transient elastography and biochemical 
markers have been used to evaluate liver fibrosis after SVR in more recent studies [84, 88]. In 
a cohort study with 10 years follow-up time, 993 patients were evaluated with paired 
Fibrotest (a score based on biochemical markers) and transient elastography measurements. 
Of 171 patients with SVR, 43 had pre-treatment cirrhosis, and of these 56% regressed to 
lower stages of fibrosis. Among patients without pre-treatment cirrhosis 12% progressed to 
cirrhosis during follow-up [88].  
The diagnostic accuracy of these non-invasive methods to detect persisting cirrhosis after 
SVR has been questioned [41, 84]. In a study comparing liver stiffness measurements with 
follow-up biopsies 61 months after SVR had been achieved, the sensitivity of transient 
elastography to detect cirrhosis was only 61% when standard pre-treatment cut-offs were 
used [41]. The combination of transient elastography and biochemical markers did not 
improve the sensitivity and biochemical markers alone failed to predict persisting fibrosis 
[84]. 
Recent published studies with repeated liver stiffness measurements up to two years after 
SVR have shown a rapid initial improvement of the liver stiffness followed by a slower or 
plateauing phase of fibrosis improvement [85-87]. Since liver elastography measures both 
fibrosis and inflammation, early liver elasticity improvement after SVR could be explained 
by a rapid reduction of the liver inflammation and less pronounced fibrosis regression. Liver 
stiffness, however, continued to improve after treatment cessation in patients who achieved 
SVR but not in non-responder patients. This would correlate better to true fibrosis regression 
[87]. 
 
3.3 OCCULT HEPATITIS C 
Negative HCV RNA 12-24 weeks after the end of antiviral treatment for chronic HCV 
infection is considered to be equivalent with virologic cure. However, several groups have 
described the presence of HCV RNA traces in serum, peripheral blood mononuclear cells 
(PBMCs) or liver tissue in patients who have achieved SVR, suggesting that these patients 
may not have completely eradicated the virus [89-91]. Furthermore, residual HCV RNA has 
been reported to increase the risk for necroinflammatory activity and fibrosis in the liver, 
indicating that residual RNA may be involved in liver disease development [92]. This has 
raised the concept of occult HCV infection, which could contribute to progressive liver 
disease after SVR and viral reactivation in immunosuppressed patients. Viral reactivation is, 
however a rare event, and there is so far no evidence of progressive fibrosis due to residual 
HCV RNA [82]. 
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4 AIMS 
The overall aim was to study the long-term clinical, histological and virological outcome 
after sustained virologic response (SVR) in patients with chronic hepatitis C. 
 
4.1 SPECIFIC AIMS 
1 To study if HCV RNA can persist in liver tissue or immune cells after successful 
treatment of chronic HCV infection, and if this correlates to clinical, immunological or 
histological outcomes. 
2 To study the long-term effect of antiviral therapy on the risk to develop HCC, liver 
complications, and liver-related death in patients with HCV related liver cirrhosis. 
3 To study the long-term risk to develop HCC after SVR has been achieved in patients 
with pre-treatment advanced fibrosis or cirrhosis and to identify risk factors associated 
with an increased risk for HCC. 
4 To study fibrosis regression and risk factors for persisting fibrosis after SVR has been 
achieved in patients with pre-treatment advanced fibrosis or cirrhosis. 
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5 MATERIALS AND METHODS 
5.1 PATIENTS AND STUDY DESIGN 
The four studies of this thesis all included patients with chronic hepatitis C cared for at 
university hospitals in Sweden. Almost 700 individual patients from seven university 
hospitals in Stockholm, Gothenburg, Linkoping, Lund, Malmo and Uppsala were included. 
The vast majority of the patients were from Karolinska University Hospital, either in Solna or 
Huddinge. There was a substantial overlap of patients between studies. The included patients 
in the different studies are described in detail below.  
 
 
Figure 6: Overview of the included patients of the different studies. 
 
5.1.1 Study I 
In this cohort study, patients with HCV-related cirrhosis were followed prospectively to 
assess the effect of antiviral treatment on clinical outcomes. The risk for HCC, liver-related 
complications, and liver-related and overall mortality was compared for patients with or 
without sustained virologic response to antiviral treatment and patients never treated for HCV 
infection. A total of 351 patients were included, and of these 303 were treated for HCV 
infection during the study period. In total 110 patients achieved SVR. Patients were recruited 
from the HCV Cirrhosis Registry, a research data base that consecutively included patients 
with a diagnosis of HCV-related liver cirrhosis at six university hospitals between January 
2001 and July 2009. Patients with decompensated cirrhosis, hepatocellular carcinoma, liver 
transplantation or hepatitis B or HIV co-infection at baseline were excluded. The majority of 
patients were recruited at the Department of Infectious Diseases and the Department of 
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Gastroenterology and Hepatology at Karolinska University Hospital. Lund University 
Hospital, Malmö University Hospital, Sahlgrenska University Hospital in Gothenburg and 
Uppsala University Hospital also contributed to the study. The baseline characteristics of the 
included patients are described in Table 1 of paper I.  
 
5.1.2 Study II 
In this cross-sectional study we investigated the possibility and clinical significance of 
residual HCV RNA after successful treatment of HCV (occult HCV infection). Patients with 
chronic HCV infection with achieved SVR after treatment with peg-interferon alpha-2b +/- 
ribavirin at least five years prior to inclusion were offered a clinical follow-up visit with a 
new liver biopsy. The liver biopsy, PBMC and serum were analyzed for residual HCV RNA 
with a highly sensitive method. The presence of residual HCV RNA was correlated to 
clinical, histological, immunological and biochemical outcomes. Between 2008 and 2010 we 
included 54 patients with all stages of pre-treatment liver fibrosis from five centers at 
Karolinska University Hospital and the University Hospitals in Linköping, Gothenburg and 
Uppsala. The baseline and follow-up characteristics of the included patients are described in 
Table 1 in paper II. 
 
5.1.3 Study III 
In this cohort study we investigated the long-term risk to develop HCC after SVR had been 
achieved in patients with pre-treatment advanced fibrosis (METAVIR F3) or cirrhosis (F4). 
We also aimed to identify risk factors associated with an elevated risk to develop HCC. The 
study included all patients with fibrosis stage F3 or F4 successfully treated for chronic HCV 
infection at Karolinska University Hospital between 1992 and 2013. Patients were identified 
from treatment records, the InfCare Hepatitis research database and the Hepatitis C Cirrhosis 
registry, as mentioned previously. Patients with HCC or liver transplantation before treatment 
or co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were 
excluded. The study ended in September 2015 and included a total of 399 patients. There was 
a significant overlap (107 patients) with the cohort from study I and some overlap (4 patients) 
with study II. The baseline characteristics of the included patients are described in Table 1 in 
paper III. 
 
5.1.4 Study IV 
In this cross-sectional study we investigated fibrosis regression and risk factors for persisting 
fibrosis after SVR had been achieved in the same cohort as in study III. Patients were offered 
a clinical follow-up visit with a liver stiffness measurement (transient elastography). At this 
visit potential risk factors for persisting fibrosis, such as age, body mass index (BMI), alcohol 
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consumption and presence of diabetes mellitus were recorded. Inclusion ended in October 
2015 and a total of 269 patients were successfully examined at a follow-up visit. Patients who 
had developed HCC, died or undergone liver transplantation before inclusion were excluded 
(n=36), and the remaining patients were lost to follow-up (n=82) or had unreliable liver 
stiffness measurements (n=15). The baseline characteristics of the included patients are 
described in Table 1 in paper IV. 
 
5.1.5 HCV treatment 
The standard of care therapy for chronic HCV infection has changed over the years covered 
by these studies and ranges from interferon monotherapy to combination therapy with 
pegylated interferon, ribavirin and direct acting antivirals (DAAs) [5, 93]. However, during 
the whole period interferon or pegylated interferon has been the back-bone of HCV 
treatment, and the last patients included in these studies achieved SVR in 2013 and were still 
treated with peg-interferon based therapies. Only a small sub-set of patients (< 10%) received 
combination therapy with DAAs. In all studies SVR was defined as a negative HCV RNA 24 
weeks after end of treatment. 
 
5.2 METHODS 
5.2.1 InfCare Hepatitis 
The InfCare Hepatitis database is a national quality registry and research database that 
includes information on demographics, histology, virology, biochemistry and treatment 
history and outcomes for patients with chronic hepatitis B and C. The database has excellent 
coverage of patients treated at Karolinska University Hospital, and was used to identify 
patients, eligible for inclusion in the studies, and also to retrieve relevant data. Other registries 
such as the HCV Cirrhosis registry described previously and treatment records were also used 
to minimize loss to follow-up.  
 
5.2.2 Virological methods 
Routine HCV RNA analysis was performed using COBAS AmpliPrep/COBAS TaqMan 
HCV (Roche Diagnostics, Mannheim, Germany) with a sensitivity of at least 15 IU / ml. The 
HCV genotype was determined with a line probe assay (Inno-LiPA HCV II, Immunogenetics 
NV, Gent, Belgium). 
In study II we used a highly sensitive method to detect minute amounts of HCV RNA in liver 
biopsies, PBMC and plasma. Liver biopsies and PBMCs (10
6 
cells per patient) were 
homogenized and plasma was concentrated 40-fold by ultracentrifugation. The extracted 
RNA was then amplified in a nested polymerase chain reaction (PCR) using two sets of 
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primers in two successive reactions. The specificity of the end product was confirmed by 
restriction digest (ThermoFisher Scientific) and sequencing of the final PCR products 
(MWG, Ebersberg, Germany). The method is described in greater detail in paper II. 
 
5.2.3 Immunological methods 
Serologies for HBV, HCV and HIV were performed at local laboratories using routine 
methods.  
In study II we measured NS3 specific antibody titers by an immunosorbent assay using 
serially 6-fold titrated plasma starting with a dilution of 1:60. We also measured the cross-
neutralizing capacity of antibodies purified from patient plasma to neutralize HCV of a non-
matching genotype (5a) [94].  
Hepatitis C specific T-cell responses were measured by enzyme-linked ImmunoSpot 
(ELISpot) and pentamer staining. We incubated PBMC with recombinant viral proteins 
(NS3, NS4, NS5a, NS5b and core), and detected IFN-γ producing cells by ELISpot 
(MabTech, Nacka Strand, Sweden and Autoimmun Diagnostica, Strassberg, Germany). NS3-
specific CD8
+ 
T-cells were detected by pentamer staining and flow cytometry. The methods 
are described in detail in paper II. 
 
5.2.4 Biochemical methods 
Biochemistry was performed at local laboratories using routine methods. 
Fibrosis indices were calculated using the AST to platelet ratio index (APRI) score: 
AST(µkat/l) / ASTULN (upper limit of normal for AST(µkat/l)) x 100 / platelet count (10
9
 /l) 
and Gothenburg University cirrhosis index (GUCI) score: AST(µkat/l) / ASTULN (µkat/l) x 
100 / platelet count (10
9
 /l ) x PT-INR [95, 96].   
 
5.2.5 Histological methods and assessment of liver fibrosis 
Pre-treatment liver fibrosis stage was determined by the original assessment of a pre-
treatment liver biopsy by a pathologist according to the METAVIR staging system [38]. 
From 2008 most patients were instead evaluated with transient elastography and pre-
treatment fibrosis stage for these patients was estimated using established clinical cut-offs for 
METAVIR stages [39]. A clinical diagnosis of liver cirrhosis was also accepted for inclusion. 
Liver stiffness measurements by transient elastography were performed with FibroScan 
(Echosense, Paris, France), using the M and XL probes, as appropriate. Only examinations 
with 10 valid measurements, a success rate of at least 60% and an inter-quartile range of less 
than 30% of the median result were considered valid. 
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In study II we performed new liver biopsies on the included patients at the follow-up visit. 
Liver biopsies were performed by the Menghini technique [97]. The pre-treatment and 
follow-up biopsies were re-assessed according to the METAVIR staging system by Magnus 
Hedenstierna and an experienced pathologist. We were blinded as to whether the biopsies 
were and performed before or after successful treatment. 
 
5.2.6 Diagnosis of hepatocellular carcinoma 
The diagnosis of HCC was based on a verified focal liver lesion by imaging techniques in 
accordance with the EASL and AASLD (American Association for the Study of Liver 
Diseases) guidelines [36, 98]. 
In study III we decided to use an unorthodox method to estimate the true date of HCC 
development. Many of the patients in this study were diagnosed with HCC late due to 
symptoms, instead of by routine HCC surveillance with ultrasound. Because of this, the true 
date of HCC development was arguably months to years before the date of diagnosis. We 
back-dated the time point of HCC diagnosis for all patients not diagnosed by routine 
surveillance, based on the assumption that a liver tumor will double its size in 6 months and 
that the smallest detectable tumor size is 1 cm [99]. 
 
5.2.7 National registries 
The Swedish national health registries include the National Causes of Death Register, the 
National Cancer Register and the National Patient Register. These registries are continually 
updated and contain information on causes of death, cancer diagnosis and inpatient and 
specialized outpatient care. The registries have an estimated coverage of 95-99% [100-102].  
We extracted data from the Swedish national health registries to obtain complete data on co-
morbidities and clinical outcomes for all patients included in our studies, regardless of if they 
were still followed-up at the clinics participating in the studies. In this way we tried to 
minimize loss to follow-up and misclassification. 
 
5.2.8 Statistical methods 
In the two cohort studies (I and III) we calculated hazard ratios (HRs) using univariate and 
multivariate Cox regression analysis to determine the association between baseline factors 
(treatment, age, sex, BMI, diabetes, alcohol consumption, genotype etc.) and the risk to 
develop HCC. Kaplan-Meier curves and incidence rates and ratios (IRs and IRRs) were 
calculated.  
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In study II we used the Mann-Whitney U-test to compare baseline and follow-up 
biochemistry and histology. The Spearman’s rank test was used to compare the distribution of 
antibody titers and IFN-γ spots for different follow-up periods. 
In study IV we used quantile regression to determine the impact of different risk factors on 
liver stiffness at follow-up and logistic regression to determine risk factors for persisting 
advanced fibrosis. The Kruskal-Wallis rank test for equality of populations was used to 
compare the distribution of fibrosis stages between different follow-up periods. 
All tests were 2-sided and a p-value of < 0.05 was considered significant. Statistical analysis 
was done with SAS 9.2 (SAS Institute, Cary, North Carolina), InStat 3 and GraphPad Prism 




All studies were performed in accordance with the Helsinki declaration and were approved 
by the Regional Ethics Committee. 
Dnr. 01-232 with amendments 2008/2054-32 and 2012/979-32 for studies I, III and IV. 
Dnr. 2008/157-31/1 for study II. 
  
 24 
6 RESULTS AND DISCUSSION 
6.1 THE CLINICAL RELEVANCE OF OCCULT HEPATITIS C (PAPER II) 
To investigate the possible presence and clinical relevance of occult HCV infection, 54 
patients with sustained virologic response at least 5 years prior to inclusion were examined at 
a clinical follow-up visit with a new liver biopsy. The included patients were evaluated for 
virological, histological, immunological and biochemical outcomes. Median follow-up time 
was 9.8 years (range 5-20 years). 
 
6.1.1 The presence of residual HCV RNA 
All included patients tested negative for HCV RNA by routine methods. Liver biopsies, 
plasma and PBMC were analyzed for minute amounts of HCV RNA using a highly sensitive 
method as described previously. All patients were negative for HCV RNA in liver biopsies 
and plasma, but three patients (6%) were positive for HCV RNA in PBMC after 8, 5 and 9 
years of follow-up. These three patients had different HCV genotypes (3a, 1a and 1b) 
excluding the possibility of contamination. One patient had different genotypes before and 
after treatment (2b and 3a), suggesting a double infection or possibly a reinfection with 
spontaneous clearance. To investigate if the detected HCV RNA persists over time the three 
patients were re-tested in PBMC after another 4-5 years, and at this time-point all three were 
negative. 
 
6.1.2 Signs of persisting liver disease 
None of the included patients had clinical signs of liver disease at follow-up, and biochemical 
liver tests and fibrosis indices had improved significantly or normalized after successful 
treatment. Two of the three patients with detectable HCV RNA had normal liver tests at 
follow-up and one had slightly elevated liver enzymes (ALT 1.06 µkat/L and AST 1.18 
µkat/L). 
Paired liver biopsies (baseline and follow-up) were available for 39/54 patients (72%). Liver 
histology (both liver fibrosis and inflammation) had improved significantly (p < 0.0001) at 
follow-up and none of the patients had progressed to a higher stage of liver fibrosis. Mean 
liver stiffness measured with FibroScan was 4.9 kPa (range 2.4-8.8 kPa) confirming the 
histological evaluation. For two of the patients with detectable HCV RNA, follow-up liver 
biopsies were available and showed no signs of inflammation or fibrosis (F0 and A0). For the 
third patient no follow-up biopsy was available, but median liver stiffness measured with 
FibroScan was 4.7 kPa corresponding to a fibrosis stage of F0-1. 
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Figure 7: Histological and immunological outcomes. Paired liver biopsies were available for 
39/54 patients. Significance was tested with the Mann-Whitney U-test and the Spearman 
rank-test. 
 
6.1.3 HCV specific immune responses 
HCV specific NS3 specific antibody titers of at least 1/360 could be detected up to 15 years 
after SVR. There was an inverse correlation between titer levels and follow-up time after 
SVR (p < 0.001), indicating waning immune response after viral clearance. The three patients 
with detectable HCV RNA at follow-up had differing NS3 antibody titers of 1/60, 1/2160 and 
1/2160, suggesting that there is no clear correlation between residual HCV RNA and 
persisting humoral immune response. The follow-up times of these three patients were below 
median in the study which could contribute to the high titers measured in two patients, but 
continued antigenic stimulation by residual HCV RNA is also possible. 
HCV specific T-cell immune responses were measured by IFN-γ ELISpot. The majority of 
patients 39/54 (72%) had at least 50 cumulative IFN-γ spots per 106 cells up to 20 years after 
SVR. As with humoral immune responses there was an inverse correlation between time after 
SVR and the level of immune response (p < 0.046). The patients with detectable HCV RNA 
had 130, 153 and 415 cumulative IFN-γ spots per 106 cells, which was comparable to other 
patients with similar follow-up times. 
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6.1.4 Discussion 
This study was unique in its broad approach to the effect of SVR on histological, virological 
and immunological outcomes, making it possible to evaluate the clinical relevance of occult 
HCV infection (residual HCV RNA in PBMC after SVR).  
Three patients (6%) tested positive for minute amounts of HCV RNA in PBMC, and this 
corresponds well to results from previous studies that have analyzed the prevalence of 
residual HCV RNA at one time point [103, 104]. However, in a longitudinal study, in which 
PBMCs were repeatedly tested 2-3 times with 3-6 month intervals, all patients (n=11) tested 
positive for residual HCV RNA at least once [90]. In another large study of 150 patients, 
residual HCV RNA could be sporadically detected up to 8 years after SVR but not thereafter 
[105]. The three patients in our study all had follow-up times below median in the study (5, 8 
and 9 years), and were all negative when re-tested after a further 4-5 years, suggesting that 
occult HCV is a transient state. 
Some studies have reported that it is possible to detect negative sense HCV RNA in PBMCs, 
indicating continued low-level replication in PBMCs after SVR has been achieved [91, 106]. 
In our study only positive sense HCV RNA was detected, and other studies have shown that 
HCV RNA can form immune-complexes with immunoglobulins and bind to the surface of 
PBMCs [107, 108]. This suggests that residual HCV RNA associated with PBMCs does not 
necessarily replicate in PBMCs, but could merely be bound to the surface of some immune 
cells.  
Chronic HCV infection has been associated with depletion of HCV specific T-cell immune 
responses [109]. This has also been observed in patients with occult hepatitis C [110]. In our 
study there was no such correlation and instead we found an inverse correlation between 
immune responses and follow-up time after SVR, indicating that successful treatment equals 
cure. This conclusion was further supported by the lack of clinical, histological and 
biochemical signs of persisting liver disease. Since it is quite possible to become re-infected 
with HCV, it seems unlikely that persistent replicating HCV infection is possible without any 
signs of active hepatitis. 
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6.2 TREATMENT AND CLINICAL OUTCOMES (PAPER I & III) 
In studies I and III we investigated the effect of HCV treatment on clinical outcomes, such as 
liver-related complications, HCC and death. Study I compared treated and untreated patients 
with cirrhosis, whereas study III focused on patients with achieved SVR, but included both 
patients with advanced fibrosis (METAVIR F3) and cirrhosis (F4). A total of 643 patients 
were included in these two cohort studies with some overlap of patients as described 
previously. Mean follow-up time was 5.3 years for study I and 8.4 years for study III, with 
follow-up times ranging from less than one year up to 8.6 and 23 years respectively. 
 
6.2.1 Liver related complications, hepatocellular carcinoma and death 
We retrieved data on clinical outcomes from patient records and the Swedish national health 
registries as described previously. In this way the risk for misclassification and loss to follow-
up was minimized. In study I incidence rates for liver-related complications (ascites, 
esophageal varicosal bleeding and hepatic encephalopathy), HCC and all-cause and liver-
related mortality were calculated. Study III focused on the risk to develop HCC but also 
included data on all-cause mortality. 
The incidence rates for liver related complications and liver-related death was significantly 
lower for patients who achieved SVR with 0.9 and 0.7 events per 100 person-years, 
compared to 3.2 and 3.0 for non-responder patients and 4.9 and 4.5 for untreated patients. 
All-cause mortality was highest among untreated patients with cirrhosis, with a mortality rate 
of 5.1 per 100 person years. This risk decreased successively for patients that received 
treatment, achieved SVR and was lowest (0.5 per 100 person years) for patients with SVR 
and pre-treatment F3 fibrosis.  
The risk to develop HCC followed the same pattern with a high risk of 5.1 per 100 person-
years for untreated patients with cirrhosis, 2.3 for treated non-responder cirrhotic patients and 
1.0 for patients with cirrhosis and SVR. The lowest risk (0.16 per 100 person years) was 




Table 2: Clinical outcomes for the different patient groups included in studies I and III. 
Follow-up time differed for different outcomes and is presented as person-years (py) for 
hepatocellular carcinoma (HCC). Incidence rates are presented as events per 100 py. 
 
In both studies the risk to develop HCC over time was analyzed. We divided the follow-up 
time to achieve similar numbers of clinical events in each time period. This resulted in a cut-
off at 3 years in study I and at 2 years in study III. In study I none of the studied outcomes 
decreased significantly after 3 years of SVR, but there was a trend for a decreased risk of any 
event after 3 years (p=0.05). Study III had a larger cohort and longer follow-up time. In this 
study the risk to develop HCC decreased significantly from 2 per 100 person years to 0.6 per 
100 person years after 2 years follow-up (p=0.039).  
 
6.2.2 Risk factors for the development of HCC 
We investigated the impact of potential risk factors at baseline on the risk to develop HCC 
after achieved SVR by Cox-regression analysis. Only six cases of HCC occurred in study I 
and the results from this study should be interpreted with caution. However, age over 50 
years at SVR and male gender were significantly associated with a higher risk to develop 
HCC, with hazard ratios (HRs) of 2.45 (95% CI 1.16-5.61, p=0.02) and 2.09 (95% CI 1.06-
4.62, p=0.047). Oher risk factors included in the analysis were alcohol consumption (<50 or 
>50 g/day), diabetes mellitus, and HCV genotype. 
In the larger study (III) of patients with SVR, 17 cases of HCC were diagnosed during 
follow-up. Only three cases occurred among patients with pre-treatment F3 fibrosis and we 
decided to exclude all patients without cirrhosis from the final regression model. We included 
age at SVR, gender, BMI, diabetes mellitus, alcohol abuse, liver steatosis, HCV genotype and 
baseline platelet count and serum albumin in the analysis. Only the presence of diabetes 
mellitus and serum albumin <35 g/dL remained significant in the multivariate analysis with 
HRs of 6.26 (95% CI 1.7-23, p=0.006) and 6.23 (95% CI 1.6-25, p=0.01). As indicated by the 
broad confidence intervals, there was a degree of statistical uncertainty due to few HCC cases 
also in this study.  
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We constructed a Kaplan-Meier graph for the cumulative incidence of HCC among patients 
with pre-treatment cirrhosis, stratified for the main risk factor diabetes mellitus (DM). The 
graph shows that the high incidence rate of HCC during the first two years after SVR is most 
pronounced in patients with diabetes mellitus, and that patients without DM have a lower and 
more stable incidence rate of HCC. 
 
 
Figure 8: Kaplan-Meier graph for the cumulative incidence of hepatocellular carcinoma for 
patients with pre-treatment cirrhosis and sustained virologic response, stratified for the 




These two studies showed that the risk to die or to develop decompensated liver disease or 
HCC is significantly reduced after treatment for chronic HCV infection. The main risk factor 
for the development of HCC was liver cirrhosis before treatment, and the association between 
low serum albumin and the risk to develop HCC indicates that this risk continues to increase 
with more advanced cirrhosis. Several studies support this conclusion, and have associated 
cirrhosis, high liver stiffness and biochemical markers of more advanced liver disease with 
the risk to develop HCC [40, 74, 111-113]. This underlines the importance of early antiviral 
treatment of chronic HCV infection before cirrhosis is established.  
Diabetes mellitus is an established independent risk factor for the development of HCC in 
patients with chronic HCV, but also in patients without chronic viral hepatitis [114-116]. The 
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mechanism for this is not fully understood, but these diseases share common risk factors such 
as obesity and liver steatosis [117]. There is also evidence of direct carcinogenic effects of 
hyperinsulinemia and insulin signaling [118]. Liver cirrhosis increases insulin resistance and 
causes hyperinsulinemia, whereas successful treatment of chronic HCV has been shown to 
decrease or even prevent the development of insulin resistance [119-121]. Previous studies on 
Asian cohorts have not identified DM as a risk factor for the development of HCC after SVR 
has been achieved, but there is growing evidence from recent studies on Western cohorts that 
support our finding [74, 112, 113, 122, 123]. This could be explained by different genetic and 
environmental backgrounds of the studied patients. 
With the access to better treatment options, more patients with advanced liver disease are 
being cured and a growing question is how to manage these patients after successful 
treatment. Continued HCC surveillance after SVR has been associated with improved HCC 
survival and current guidelines recommend continued HCC surveillance by ultrasound every 
6 months for patients with a high pre-treatment risk to develop HCC [36, 98, 124]. In our 
study only three patients with pre-treatment F3 fibrosis developed HCC during almost 2000 
person years of follow-up time. The incidence rate for this patient group was well below the 
1.5% incidence threshold usually suggested for HCC surveillance to be cost effective in 
patients with cirrhosis [36]. Patients without cirrhosis and patients successfully treated for 
HCV will, as these studies show, have a longer life expectancy and more life-years to gain 
from continued surveillance. As a comparison a HCC incidence threshold of 0.2% has been 
suggested for surveillance in non-cirrhotic patients with chronic HBV infection [36]. 
However, the risk to develop HCC after SVR for patients with F3 fibrosis was only 0.16 per 
100 person years in our study and it is questionable if continued surveillance for this group is 
cost-effective. We also showed that for patients with cirrhosis, the risk to develop HCC 
decreases with longer follow-up time after SVR. This indicates that there might be a time 
point after SVR when it is no longer reasonable to continue HCC surveillance, especially in 
patients that lack other important risk factors such as diabetes mellitus. However, in our 
studies the incidence rate of HCC for cirrhotic patients was still at levels that warrant 
continued surveillance, and further studies and cost-effectiveness analysis are needed to 
decide this question. 
All patients in our studies were treated with INF-containing regimens, and another important 
question is if we can apply the results on patients treated with DAAs. Early reports from 
cohorts treated with IFN-free regimens have shown unexpected high incidence rates of HCC, 
mainly among patients previously treated for HCC [125, 126]. This has been attributed to 
different immunological responses to IFN-containing and IFN-free regimens and the loss of 
IFN-mediated anti-proliferative effects on HCC [126, 127]. However, other studies have not 
identified an increased risk for HCC with DAA treatment, and it is possible that the observed 
high incidence is a consequence of selection bias [128, 129]. Patients that previously did not 
tolerate or responded poorly to IFN-based therapy had the highest risk to develop HCC, and 
are now effectively treated with DAAs [130]. The cohort in study III included all patients 
with F3 or F4 fibrosis successfully treated at Karolinska University Hospital between 1991 
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and 2013 (n=399). These patients were highly selected before treatment and only a small 
proportion achieved SVR and could be included in the cohort. Between 2014 and 2016 
another 701 patients with F3 and F4 fibrosis have achieved SVR at Karolinska University 
Hospital after treatment with DAA, clearly illustrating that these populations are not 
comparable. As a consequence we need to be careful when we apply results from IFN-era 
studies on DAA-era populations. 
 
6.3 FIBROSIS REGRESSION AFTER SVR (PAPER IV) 
To investigate fibrosis regression after SVR, we performed a cross-sectional study on the 
cohort from study III. Of the 399 patients in the cohort, 269 (67%) were successfully 
examined with transient elastography (FibroScan) at a follow-up visit. 
 
6.3.1 Liver stiffness after SVR 
A majority of the included patients had a low liver stiffness at follow-up corresponding to 
METAVIR F0-1 fibrosis according to pre-treatment cut-offs for METAVIR fibrosis stages. 
The median liver stiffness at follow-up was 6.6 kPa (range 2-57), with significantly higher 
median liver stiffness for patients with pre-treatment cirrhosis (8.5 kPa, 95% CI 7-9.1) than 
for patients with F3 fibrosis (6 kPa, 95% CI 5.5-6.4), (p<0.0001). Only one measurement of 
liver stiffness was available for each patient and the follow-up time from SVR varied greatly 
between patients. To investigate a possible effect of longer follow-up time on fibrosis 
regression, we divided the include patients into groups based on 5 year follow-up periods.  
This could introduce bias, since patients with longer follow-up times were treated with older 
and less effective treatment regimens, and might not be comparable to more recently treated 
patients. However, when baseline characteristics were compared the groups did not differ 
greatly. The included patients are described in detail in paper IV. 
Liver stiffness improved early for patients with pre-treatment F3 fibrosis and the distribution 
of liver stiffness and corresponding METAVIR fibrosis stages then remained stable over 
time. Liver stiffness improved more slowly in cirrhotic patients but continued to improve 
with longer follow-up time. After more than 10 years of follow-up the difference in liver 
stiffness between patients with pre-treatment F4 and F3 fibrosis had decreased and was no 
longer significant with 7.0 kPa (95% CI 5.6-83) and 5.6 kPa (95% CI 4.5-6.7) respectively 
(p=0.13). 
6.3.2 Risk factors for persisting advanced fibrosis 
Most patients improved their fibrosis stage after SVR, but 24% had a liver stiffness ≥ 9.5 kPa 
indicating persisting advanced fibrosis according to pre-treatment cut-offs for METAVIR 
stages. Among patients with pre-treatment cirrhosis this proportion decreased with longer 
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follow-up time from 48% for patients with < 5 years of follow-up to 36 % for patients with 5-
10 years of follow-up, and 21% when follow-up time was > 10 years (p=0.02). 
 
 
Figure 9: The distribution of fibrosis stages at follow-up by METAVIR fibrosis stage at 
baseline and 5-year follow-up period. 
 
We estimated the risk for persisting advanced fibrosis at follow-up, defined as a liver stiffness 
≥ 9.5 kPa, by calculating odds ratios (ORs) with logistic regression for patients with different 
risk factors. The analysis included age, gender, baseline fibrosis stage, BMI, the presence of 
diabetes mellitus and alcohol consumption. In the multivariate analysis, pre-treatment 
cirrhosis, age ≥ 55 years at SVR and BMI ≥ 25 kg/m2 at follow-up remained significant risk 
factors for persisting advanced fibrosis with ORs of 3.9 (95 % CI 2.0-7.2), 2.3 (95 % CI 1.2-
4.3) and 2.3 (95 % CI 1.1-4.6), respectively. 
 
6.3.3 Discussion 
This study confirmed that fibrosis and even cirrhosis can regress after SVR has been achieved 
in a vast majority of patients. Older patients who had already developed cirrhosis before 
treatment had higher liver stiffness after successful treatment, stressing the importance of 
early HCV treatment before cirrhosis is established. High BMI was also identified as an 
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important risk factor for high liver stiffness after SVR, again identifying the metabolic 
syndrome as an important cause of liver disease [117]. 
A third of the included patients had long follow-up times of 10-20 years after SVR. This 
group had significantly lower liver-stiffness than patients with shorter follow-up times after 
SVR, indicating that fibrosis regression is a process that continues for many years. This trend 
was mainly seen in patients with pre-treatment cirrhosis and the difference in liver-stiffness 
between patients with pre-treatment F3 and F4 fibrosis was no longer significant >10 years 
after SVR. This suggests that more profound changes of liver histology, such as the nodular 
architecture typical for cirrhotic livers take many years to improve. Studies on liver histology 
after SVR has shown that early improvement of liver-stiffness after SVR was associated with 
reduced necroinflammatory activity and reduced collagen content of the liver [41, 81]. This 
was seen both in patients with cirrhosis regression and in patients who maintained a cirrhotic 
nodular liver architecture [41]. With the long follow-up time of this study, it is unlikely that 
our results only reflect early changes in inflammation and collagen content, and we conclude 
that even cirrhosis will regress over time after successful treatment of chronic HCV. 
The major weakness of this study was the cross-sectional design and the fact that we used 
transient elastography instead of liver biopsies to evaluate persisting fibrosis. There are no 
established liver stiffness cut-offs for corresponding METAVIR fibrosis stages after SVR has 
been achieved and the sensitivity of transient elastography to detect persisting cirrhosis has 
been questioned [41]. Recent studies with repeated liver stiffness measurements up to two 
years after SVR show that liver stiffness decreases rapidly after antiviral treatment probably 
due to decreased inflammation [85-87]. However, these studies also show that liver stiffness 




The four studies of this thesis provide encouraging evidence of the positive effects of 
successful treatment of chronic HCV infection.  
We have shown that even though minute amounts of HCV RNA can be detected up to 9 
years after SVR has been achieved, this does not correlate to continued liver disease. On the 
contrary, the persistence of HCV RNA in PBMC seems to be transient and HCV specific 
immune responses wane with time after SVR indicating complete virologic clearance. 
Several studies have shown that successful treatment reduces the risk for liver-related 
complications and hepatocellular carcinoma. Our studies added to that knowledge by 
investigating the effect on all cause- and liver-related mortality and by identifying risk factors 
for the development of HCC. With long follow-up times it was also possible to study how the 
risk for HCC changes over time. 
Our studies have shown that treatment reduces the risk for all clinical outcomes, but that a 
risk for HCC remains at least 15 years after SVR has been achieved. The risk to develop 
HCC for patients with advanced fibrosis without cirrhosis was low after achieved SVR, and 
the need for continued HCC surveillance for this group is questionable. Patients with 
cirrhosis before treatment had a higher risk to develop HCC after SVR had achieved, but our 
studies showed that this risk diminishes over time. This suggests that there could be a time-
point even for this group when the risk for HCC is reduced below the threshold that warrants 
continued HCC surveillance. 
Furthermore, we showed that liver fibrosis and even cirrhosis will improve after successful 
treatment of HCV infection, and that this process continues with time. The main risk factors 
for persisting advanced fibrosis after SVR had been achieved was established cirrhosis before 
treatment, older age and high body mass index. Metabolic disease is strongly and 
independently associated with liver disease, and these studies show that metabolic disease is 
also an important risk factor for persisting fibrosis and the risk to develop HCC in patients 
with SVR after treatment of chronic HCV infection. 
A remaining question is how persisting cirrhosis after SVR correlates to the risk to develop 
HCC. We have shown that both cirrhosis and the risk to develop HCC diminishes with longer 
follow-up time after SVR, but our studies were not designed to correlated fibrosis regression 
with HCC risk. Six of the patients included in our studies developed HCC after they were 
examined with transient elastography, and two of these had a liver stiffness corresponding to 
a fibrosis stage F0-1 at follow-up. This indicates that liver stiffness after SVR is a poor 
prognostic marker for the risk to develop HCC, but larger studies designed to investigate this 
are needed. 
All patients in these four studies were treated with IFN-based therapy, and our results should 
be interpreted with caution when applied to patients treated with DAAs. The long-term effect 
of SVR is likely to be independent of the type of therapy, but with IFN-free treatment we are 
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able to cure patients with more advanced liver disease and a higher baseline risk for liver 
related complications and HCC. 
To conclude, virologic cure (SVR) dramatically improves the outcome for patients with 
chronic HCV infection, but patients with risk factors such as established cirrhosis and 
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